Ongoing physician oversight ensures safe and comfortable progress
Sulfur burps affect anywhere from 2% to 7% of people taking GLP-1 receptor agonists like semaglutide , tirzepatide , and liraglutide, according to clinical trial data filed with the FDA
This highlights the need to evaluate not only the quality of adverse events reported, but also the proportion of cutaneous adverse events compared to all adverse events. Most commonly reported were cases of rash and pruritus, followed by alopecia and hyperhidrosis
You can easily mitigate them through management
By enhancing satiety signals and slowing gastric emptying, GLP-1 therapy can help patients feel fuller after meals and reduce persistent hunger between meals
While promising, these innovations are still being researched and require further clinical validation [25]